Keros insider sells 1,224 shares at $10.29

Keros Therapeutics, Inc. (KROS) reported that Annita Tanini, Corp. Controller & VP, Finance, sold 1,224 shares of common stock on 2026-08-18 at a weighted average price of $10.29 per share.

Rhea-AI Filing Summary

Keros Therapeutics, Inc. (KROS) reported that Annita Tanini, Corp. Controller & VP, Finance, sold 1,224 shares of common stock on 2026-08-18 at a weighted average price of $10.29 per share. The company states these were automatic "sell-to-cover" transactions to satisfy tax withholding on vested restricted stock units, and Ms. Tanini now holds 45,144 shares directly.

Insider Trade Summary

Net Seller: 1,224 shares

Net Sell 1 txn

Insider Tanini Annita

Role Corp. Controller & VP, Finance

Sold 1,224 shs ($13K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	1,224	$10.29	$13K

Holdings After Transaction: Common Stock — 45,144 shares (Direct)

Footnotes (2)

1. F1. The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.14 to $10.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 1,224 shares Weighted average sale price: $10.29 per share Sale price range: $10.14 to $10.50 per share +1 more

4 metrics

Shares sold 1,224 shares Common Stock sold on 2026-08-18

Weighted average sale price $10.29 per share Common Stock sale on 2026-08-18

Sale price range $10.14 to $10.50 per share Multiple transactions included in the weighted average price

Shares owned after transaction 45,144 shares Direct ownership following the 2026-08-18 sale

Key Terms

sell-to-cover policy, restricted stock units, weighted average price

3 terms

sell-to-cover policy financial

"The Issuer has adopted a "sell-to-cover" policy to satisfy the tax"

restricted stock units financial

"tax withholding obligations in connection with the vesting of restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

FAQ

What insider transaction did KROS report for Annita Tanini on this Form 4?

Annita Tanini sold 1,224 shares of Keros Therapeutics, Inc. common stock on 2026-08-18. According to the company, the sale was an automatic "sell-to-cover" transaction to satisfy tax withholding obligations related to the vesting of restricted stock units.

At what price were the KROS shares sold in this Form 4 transaction?

The reported price is a weighted average of $10.29 per share. The filing explains that the shares were sold in multiple transactions at prices ranging from $10.14 to $10.50 inclusive.

How many KROS shares does Annita Tanini own after this reported sale?

After the reported sale, Annita Tanini directly owns 45,144 shares of Keros Therapeutics, Inc. common stock. This figure is reported as the total shares beneficially owned following the transaction.

Was the KROS insider sale part of a discretionary trading decision?

The company states the sale was automatic under an adopted "sell-to-cover" policy. The shares were sold solely to cover tax withholding obligations from the vesting of restricted stock units and were not at the discretion of the reporting person.

Does this KROS Form 4 mention a Rule 10b5-1 trading plan?

The Rule 10b5-1 checkbox is not checked for this filing. Instead, the company describes the transaction as occurring under its "sell-to-cover" policy for tax withholding on restricted stock unit vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/20/2026 - 04:10 PM Accepted by SEC EDGAR 08/20/2026 - 04:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tanini Annita

(Last) (First) (Middle)

C/O KEROS THERAPEUTICS, INC.

1050 WALTHAM STREET, SUITE 302

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Keros Therapeutics, Inc. [ KROS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Corp. Controller & VP, Finance

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/18/2026		S		1,224(1)	D	$10.29(2)	45,144	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.14 to $10.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Esther Cho, Attorney-in-Fact	08/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)